O'Donnell Elizabeth K, Raje Noopur S
Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Massachusetts General Hospital, Boston, MA, USA.
Ther Adv Hematol. 2017 Feb;8(2):41-53. doi: 10.1177/2040620716682490. Epub 2016 Dec 26.
Across all cancers, monoclonal antibodies have emerged as a potential strategy for cancer therapy. Monoclonal antibodies target antigens expressed on the surface of cancer cells and accessory cells. This targeted approach uses the host's immune system to promote the killing of cancer cells. Multiple myeloma (MM) is the second most common hematologic malignancy that remains incurable in the majority of patients. The treatment of MM has evolved dramatically over the past decade and continues to evolve with the approval of four new drugs in 2015. Most recently the United States Food and Drug Administration (US FDA) approved two monoclonal antibodies for the treatment of this disease. Monoclonal antibodies are generally well-tolerated and offer a novel method of action for treated relapsed and refractory disease and are now being studied in the upfront setting. In this article, we review the evidence for the existing approved monoclonal antibodies and discuss promising targeted therapies and innovative strategies for the treatment of MM.
在所有癌症中，单克隆抗体已成为一种潜在的癌症治疗策略。单克隆抗体靶向癌细胞和辅助细胞表面表达的抗原。这种靶向方法利用宿主的免疫系统来促进癌细胞的杀伤。多发性骨髓瘤（MM）是第二常见的血液系统恶性肿瘤，大多数患者仍无法治愈。在过去十年中，MM的治疗发生了巨大变化，并且随着2015年四种新药的获批仍在不断发展。最近，美国食品药品监督管理局（US FDA）批准了两种单克隆抗体用于治疗这种疾病。单克隆抗体通常耐受性良好，为治疗复发和难治性疾病提供了一种新的作用方式，目前正在前期治疗中进行研究。在本文中，我们回顾了现有获批单克隆抗体的证据，并讨论了治疗MM的有前景的靶向疗法和创新策略。
